The operating room sits at the intersection of several factors that make it one of the highest-risk environments for controlled substance diversion in the entire healthcare system. High-volume opioid use, a large number of credentialed providers with legitimate access, single-provider administration at the point of care, and waste events that are physically difficult to witness all converge in a setting where close supervision is structurally limited by the demands of patient care. Understanding why the OR is high risk — and what specific controls address each vulnerability — is essential for any perioperative program that takes diversion prevention seriously.

Why the OR Is a High-Risk Setting

Several structural features of the operating environment distinguish it from other controlled substance dispensing settings:

  • High-volume, high-potency opioid use: Fentanyl, hydromorphone, sufentanil, and morphine are administered in therapeutic doses that represent high street value in small volumes. A single case may involve hundreds of micrograms of fentanyl, most or all of which may be discarded as waste if the patient requires less than the prepared dose.
  • Single-provider administration: Unlike a hospital unit where a nurse administers medication and a second nurse may be nearby, anesthesia is typically administered by a single provider working largely independently within the operative field. There is no routine second-nurse verification of administration events.
  • Difficult-to-witness waste: Wasting a partial dose in a syringe during an active surgical case requires a witness to be present at the exact moment of disposal. In practice, the circulating nurse, surgical technician, and other OR staff are occupied with patient care tasks, making contemporaneous waste witnessing logistically challenging.
  • Large number of providers with legitimate access: Anesthesiologists, certified registered nurse anesthetists (CRNAs), anesthesia assistants, anesthesia technicians, and some surgical staff all have legitimate access to controlled substances in the perioperative environment. The larger the access group, the more difficult it is to detect anomalous behavior by any individual within it.

These factors do not mean diversion is inevitable in OR settings — they mean that OR-specific controls must be designed for the OR environment, not simply extended from general pharmacy or nursing unit controls that were not built for single-provider, high-volume, operationally intense settings.

Control 1: Anesthesia Cart Security Between Cases

The anesthesia provider's medication cart is the primary point of controlled substance storage and preparation during a case. Between cases — during room turnover, when the provider may be absent and multiple staff are moving through the room — the cart must be secured to prevent unauthorized access.

  • Anesthesia carts must be locked at the end of every case, before the provider leaves the room. This is not optional: an unlocked, unattended cart during turnover is a direct access vulnerability.
  • Every cart should be inventoried against the prior case's dispensing record before the next case begins. Discrepancies must be documented before proceeding, not deferred to end-of-day reconciliation.
  • Access to cart contents during the provider's absence should require a second authorized individual to be present — not just to observe, but to document what was accessed and why.

Cart security is the physical foundation of OR-based controlled substance control. Without it, documentation controls and surveillance analytics are operating on a corrupted record.

Control 2: Witnessed Waste Per Case

Witnessed waste documentation is the primary verification mechanism for controlled substance accountability in anesthesia. The requirement is that a qualified witness — typically a registered nurse or another anesthesia provider — observes the disposal of unused medication in real time, for every case where waste occurs.

  • Waste must be witnessed at the case level, not aggregated and documented end-of-day or end-of-shift. A provider who documents eight cases' worth of waste at the end of a ten-hour shift cannot provide meaningful accountability for any individual case.
  • The witness must observe the disposal event itself — the physical act of wasting the contents of the syringe or vial — not simply co-sign a record that the provider asserts is accurate. Post-hoc attestation is not witnessed waste.
  • Wasted quantities must be consistent with the dispensed dose and the documented administration for the patient. If a provider dispensed 200 mcg of fentanyl and documents having administered 100 mcg and wasted 100 mcg, the witness must confirm observing the disposal of a quantity consistent with 100 mcg — not simply that some waste occurred.

Witnessed waste compliance rates — the percentage of waste events that have a documented contemporaneous witness — should be tracked at the provider level and reviewed as a surveillance metric. A provider whose witnessed waste rate is significantly lower than peers is a surveillance signal that warrants review.

Control 3: Controlled Substance Storage Within the OR Suite

Controlled substances dispensed for OR use should be stored in a secured, access-controlled location within or immediately adjacent to the OR suite — not transported through unsecured areas or stored in locations accessible to unauthorized staff. Where an automated dispensing cabinet or equivalent secured storage is available within the OR suite, it should be used as the dispensing point rather than bringing bulk quantities from a central pharmacy location without a secure chain of custody.

  • Secured storage within the suite eliminates the transport vulnerability and keeps the custody chain short and auditable.
  • Access logs for in-suite storage must capture the same data as any other ADC or controlled substance access point: user, time, drug, quantity, and patient association.
  • Tamper-evident packaging from the central pharmacy to the suite-level storage — sealed transport containers with documentation of who sealed and who received — closes the transport gap.

Control 4: Closed-Loop Reconciliation

Closed-loop reconciliation means that every controlled substance dispensed for an OR case can be fully accounted for at case close — either administered (with the dose documented in the anesthesia record) or wasted (with a contemporaneous witness). No quantity should be unaccounted for at case close.

  • Kit checkout and return logs must document the specific drugs and quantities dispensed for each case and returned or wasted at its conclusion. These logs must be reconciled within 24 hours of the case, not deferred to a weekly audit.
  • The reconciliation record should compare the anesthesia provider's dispense record against the pharmacy's dispense record and the patient's medication administration record. Discrepancies between these three data sources — particularly systematic discrepancies associated with a specific provider — are a significant surveillance signal.
  • Any unreconciled quantity at 24 hours must trigger a documented investigation. "The paperwork was not completed" is not an acceptable explanation for a missing controlled substance quantity.

Control 5: Provider-Level Surveillance

Surveillance in the OR context means analyzing provider-specific patterns in waste documentation, override events, and case-to-case dispensing behavior. Unit-level or shift-level analysis is insufficient in a setting where individual providers operate with substantial autonomy.

  • Waste rate per case — total wasted divided by total dispensed, per provider per drug — should be calculated monthly and compared against the peer cohort (providers in the same role, the same procedure types, the same case volume range).
  • Case count-to-dispense ratio: if a provider consistently dispenses more controlled substance per case than peers handling similar procedures, that excess should be reconcilable in the waste record. If it is not, the gap is a discrepancy.
  • Temporal patterns: providers who document all waste at the end of the day rather than at each case close, or who have significantly lower witnessed-waste rates than peers, should be flagged for supervisory review.

These metrics are best reviewed by the diversion prevention officer in collaboration with the chief of anesthesia and the perioperative nursing director — not by a single department in isolation. Interdisciplinary review reduces the risk that a provider relationship or professional deference suppresses a legitimate concern.

Camera Coverage: The Fish-Eye Strategy

Camera coverage of OR-based controlled substance storage and waste areas is one of the most effective — and most commonly misconfigured — physical controls in the perioperative setting. Standard ceiling-mounted cameras capture the top of the anesthesia cart and the back of the provider's head, providing little evidentiary value for a waste event or syringe substitution.

Fish-eye lens cameras positioned to capture the workspace in front of the anesthesia cart — at approximately counter height, facing outward — provide a view of the provider's hands, the syringe or vial, and the waste container. This positioning captures the actions that matter for documenting or refuting a diversion allegation, rather than simply confirming that someone was present. For detailed guidance on camera positioning and retention requirements, see the camera placement guide.

Access Minimization

The number of individuals with access to OR-based controlled substance storage should be limited to the smallest group necessary for clinical operations. Every additional person in the access group is an additional potential subject in a diversion investigation and an additional complexity in access log review. Access should be granted by specific role and documented in writing, with regular reviews — at least annually — to remove access for staff who have changed roles, left the department, or are on extended leave.

This principle also applies to override authorizations. Override capability should not be granted broadly to all credentialed OR staff — it should be limited to the provider categories for whom it is clinically necessary, with all override events reviewed as part of the monthly surveillance cycle.

Supporting Non-Punitive Reporting for Anesthesia Providers

Anesthesia providers who develop a substance use disorder face a particularly difficult reporting environment. Their colleagues — who may observe concerning behavior — are often peers with long professional relationships, and the stakes of a diversion allegation (DEA investigation, state license action, loss of clinical privileges) make colleagues reluctant to report. This reluctance is a real barrier to early intervention and increases the likelihood that a provider reaches a crisis point before the organization becomes aware of the problem.

A non-punitive reporting culture in the OR specifically means:

  • A confidential reporting channel that reaches the diversion prevention officer and the chief of anesthesia — not the provider's direct supervisor — so that a reporter does not have to navigate a departmental relationship to raise a concern
  • Clear communication that fitness-for-duty concerns will be handled through a health and assistance pathway rather than an automatic disciplinary pathway, where that option is available under the organization's policies and applicable state law
  • Visible leadership commitment from the chief of anesthesia and the perioperative nursing director that early reporting is a professional obligation and a patient safety act — not a betrayal of a colleague

What to Do When a Pattern Emerges

When surveillance data or a colleague's report generates a credible concern about an anesthesia provider, the response must be deliberate and structured:

  1. Escalate to the diversion prevention officer immediately. Do not attempt to resolve the concern informally, confront the provider, or wait for additional evidence. The DPO is the appropriate authority to assess the signal and initiate a structured review.
  2. Preserve records without alerting the subject. Secure access logs, camera footage, waste documentation, and case records before the subject has an opportunity to become aware that a review is underway. Evidence preservation is time-sensitive.
  3. Conduct a preliminary case review. The DPO, in consultation with the chief of anesthesia and compliance, should evaluate the available data against the significant-loss criteria under 21 C.F.R. §1301.74(c) and determine whether the preliminary notification obligation has been triggered.
  4. Do not accuse, and do not clear prematurely. Investigation is the appropriate response to a credible pattern — neither an accusation nor a reassurance that nothing is wrong. Premature clearance of a subject who is later found to have been diverting creates significant organizational liability.

For a detailed investigation framework including interview guides and documentation standards, see the investigation interview guide. For a full program assessment that includes perioperative-specific controls, use the hospital pharmacy diversion prevention checklist.

Anesthesia diversion detection is also on the agenda at the IHFDA 11th Annual Conference (Sep 28–29, 2026) — see our guide for the full session list and registration deadline.